Vatelizumab

Drug Profile

Vatelizumab

Alternative Names: CHR-1103; GBR 500; SAR 339658; TMC-2003; UNII-A4R7G50030

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chromos Molecular Systems
  • Developer Glenmark Pharmaceuticals S.A.; Sanofi
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Cell adhesion molecule inhibitors; Immunosuppressants; Integrin alpha2beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • No development reported Cancer
  • Discontinued Chronic obstructive pulmonary disease; Multiple sclerosis; Retinal disorders; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 12 Jul 2016 Sanofi terminates a phase II/III trial in Multiple sclerosis based on the planned interim analysis (NCT02222948)
  • 01 Jan 2016 Vatelizumab is available for licensing as of 01 Jan 2016. http://www.glenmarkpharma.com/GLN_NWS/homepage.aspx?res=P_GLN
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top